Q-omics provides the consensus-scored CST9 profile across patient tissues and cancer cell-line models. CST9 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CST9 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, CST9 RNA expression shows 8,129 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where CST9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CST9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CST9 survival associations across molecular data types. CST9 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CST9 RNA expression–survival associations across cancer types. High CST9 expression shows unfavorable associations in KIRC, THCA, PAAD and COAD, but favorable associations in BRCA and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for CST9 RNA expression.
This table summarizes CST9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CST9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CST9 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in COAD and LUSC. The KIRC box plot shows higher CST9 RNA expression in normal versus tumor tissue (log2 FC = −0.583, t-test p < 0.001).
This table shows molecular features associated with CST9 in patient tissues and cancer cell lines. In patient samples, CST9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CST9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
